

**Supplementary Table 1.** Changes in Antibiotic Nonsusceptibility Among Serotype 19A Isolates  
After PCV7 or PCV13 Introduction

Study	Condition	Country	Agent	Antimicrobial Nonsusceptibility, %	
				Pre-PCV7	Post-PCV7
PCV7					
Calatayud et al	IPD	Spain	Macrolides	7.41	17.65
Fenoll et al	Noninvasive	Spain	Penicillin	18.2	71.4 ( <i>P</i> =0.003)
			Amoxicillin	0	
		Belgium	Penicillin	0–50	21
			Macrolides	0–50	67
Hanquet et al	IPD	Spain	Penicillin	0–50	48
			Macrolides	0–50	61
		France	Penicillin	0–50	86
			Macrolides	0–50	77
Cho et al	Respiratory symptoms	Korea	Penicillin	100	100
Kyaw et al	IPD	United States	Penicillin	2.0*	8.3*
PCV13					
Dagan, et al	Healthy children	Israel	Multidrug resistant	Odds ratio (95% CI) for new serotype 19A acquisition, PCV13 vaccination/PCV7 vaccination = 0.58 (0.37, 0.93)	

IPD=invasive pneumococcal disease; PCV7=7-valent pneumococcal conjugate vaccine;  
PCV13=13-valent pneumococcal conjugate vaccine.

\*Per 100,000 population.

## Supplementary Material References

Calatayud L, Ardanuy C, Tubau F, et al. Serotype and genotype replacement among macrolide-resistant invasive *Pneumococci* in adults: mechanisms of resistance and association with different transposons. *J Clin Microbiol* 2010;48:1310-6

Cho EY, Kang HM, Lee J, et al. Changes in serotype distribution and antibiotic resistance of nasopharyngeal isolates of *Streptococcus pneumoniae* from children in Korea, after optional use of the 7-valent conjugate vaccine. *J Korean Med Sci* 2012;27:716-22

Dagan R, Juergens C, Trammel J, et al. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible *Streptococcus pneumoniae*. *J Infect Dis* 2015;211:1144-53

Fenoll A, Aguilar L, Gimenez MJ, et al. Variations in serotypes and susceptibility of adult non-invasive *Streptococcus pneumoniae* isolates between the periods before (May 2000-May 2001) and 10 years after (May 2010-May 2011) introduction of conjugate vaccines for child immunisation in Spain. *Int J Antimicrob Agents* 2012;40:18-23

Hanquet G, Kissling E, Fenoll A, et al. Pneumococcal serotypes in children in 4 European countries. *Emerg Infect Dis* 2010;16:1428-39

Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant *Streptococcus pneumoniae*. *N Engl J Med* 2006;354:1455-63